SCHEMBL5458044

SCHEMBL5458044

CSc1cccc(NC(=O)Nc2sc3c(c2C(N)=O)CCOC3)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.57
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
EPHB4 P54760 1/20 0.51
KDM4E B2RXH2 2/20 0.47
MAPT P10636 3/20 0.47
TP53 P04637 1/20 0.47
POLB P06746 1/20 0.47
MAPK1 P28482 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TNIK Q9UKE5 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
USP2 O75604 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5458342 0.88 CFTR (0.59) CFTRMEN1KMT2ANPC1RAB9A
SCHEMBL5451652 0.87 CFTR (0.60) CFTRMEN1KMT2ANPC1RAB9A
SCHEMBL5466862 0.86 CFTR (0.57) CFTRMEN1KMT2ANPC1RAB9A
SCHEMBL5467205 0.86 CFTR (0.56) CFTRMEN1KMT2ANPC1RAB9A
SCHEMBL5448351 0.85 CFTR (0.55) CFTRMEN1KMT2ANPC1RAB9A
SCHEMBL5454365 0.85 CFTR (0.55) CFTRMEN1KMT2ANPC1RAB9A
SCHEMBL5457654 0.85 CFTR (0.55) CFTRMEN1KMT2ANPC1RAB9A
SCHEMBL5449672 0.85 CFTR (0.55) CFTRMEN1KMT2ANPC1RAB9A
SCHEMBL5455489 0.85 CFTR (0.55) CFTRMEN1KMT2ANPC1RAB9A
SCHEMBL5455947 0.85 MEN1 (0.65) CFTRMEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 CFTR 2030/4885MEN1 2891/4885KMT2A 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.